University of Hertfordshire

From the same journal

By the same authors

  • David Castle
  • Francesca Beilharz
  • Katharine A Phillips
  • Vlasios Brakoulias
  • Lynne M Drummond
  • Eric Hollander
  • Konstantinos Ioannidis
  • Stefano Pallanti
  • Samuel R. Chamberlain
  • Susan L Rossell
  • David Veale
  • Sabine Wilhelm
  • Michael Van Ameringen
  • Bernardo Dell'Osso
  • Jose M. Menchon
  • Naomi Fineberg
View graph of relations
Original languageEnglish
JournalInternational Clinical Psychopharmacology
Publication statusAccepted/In press - 16 Oct 2020

Abstract

Body dysmorphic disorder (BDD) is characterised by a preoccupation with a perceived appearance flaw or flaws that are not observable to others. BDD is associated with distress and impairment of functioning. Psychiatric comorbidities, including depression, social anxiety and obsessive-compulsive disorder are common and impact treatment. Treatment should encompass psychoeducation, particularly addressing the dangers associated with cosmetic procedures, and may require high doses of SSRI* and protracted periods to establish full benefit. If there is an inadequate response to SSRIs, various adjunctive medications can be employed including atypical antipsychotics*, anxiolytics* and the anticonvulsant levetiracetam*. However, large scale randomised controlled trials are lacking and BDD is not an approved indication for these medications. Oxytocin* may have a potential role in treating BDD, but this requires further exploration. Cognitive-behavioural therapy has good evidence for efficacy for BDD, and on-line and telephone-assisted forms of therapy are showing promise. CBT for BDD should be customised to address such issues as mirror use, perturbations of gaze and misinterpretation of others’ emotions, as well as overvalued ideas about how others view the individual.

ID: 22817871